Next Article in Journal
Grandine A, a New Proaporphine Alkaloid from the Bark of Phoebe grandis
Next Article in Special Issue
Thermus thermophilus Strains Active in Purine Nucleoside Synthesis
Previous Article in Journal
Chemical Composition and Antimicrobial Properties of Piper ovatum Vahl
Previous Article in Special Issue
Differential Cytotoxicity of MEX: a Component of Neem Oil Whose Action Is Exerted at the Cell Membrane Level
Molecules 2009, 14(3), 1183-1226; doi:10.3390/molecules14031183
Review

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

* , ,  and
Received: 6 January 2009; in revised form: 27 February 2009 / Accepted: 10 March 2009 / Published: 23 March 2009
(This article belongs to the Special Issue Nucleic Acids)
Download PDF [456 KB, uploaded 18 June 2014]
Abstract: For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials.
Keywords: Fludarabine; Cladribine; Pentostatin; Clofarabine; Nelarabine; Forodesine; Purine nucleoside analogues; Mechanism of action; Clinical application Fludarabine; Cladribine; Pentostatin; Clofarabine; Nelarabine; Forodesine; Purine nucleoside analogues; Mechanism of action; Clinical application
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Robak, T.; Korycka, A.; Lech-Maranda, E.; Robak, P. Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. Molecules 2009, 14, 1183-1226.

AMA Style

Robak T, Korycka A, Lech-Maranda E, Robak P. Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. Molecules. 2009; 14(3):1183-1226.

Chicago/Turabian Style

Robak, Tadeusz; Korycka, Anna; Lech-Maranda, Ewa; Robak, Pawel. 2009. "Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases." Molecules 14, no. 3: 1183-1226.


Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert